Abstract
We are delighted to inform the readership of Current Oncology that Dr. Richard J. Ablin, from the University of Arizona College of Medicine and the Arizona Cancer Center, has agreed to join Dr. Phil Gold as co-deputy editor. We welcome Richard, who has served on the editorial board of Current Oncology since 1998 and who is currently co-editor with Phil Gold of our section on Updates and Developments in Oncology. In their respective roles, Phil and Richard will work together, with the help of our section editors, to expand the base of submissions from across Canada and the United States. In this regard, we look to you, our readership, for input about the kind of material that you would like to see—and indeed for original articles for publication in your specific areas of interest and expertise, and for reviews of areas that have experienced rapid progress on the clinical side. Furthermore, Phil and Richard, together with other members of our staff, will be interfacing with industry and other stakeholders in the oncology community throughout North America while promoting Current Oncology and working to further enhance the impact value of the journal. We anticipate that these exciting changes will bring Current Oncology to the next level, thereby filling a niche for not only for specialists in clinical oncology, but also for family physicians who have taken on major responsibilities in meeting the needs of cancer patients. In the process, we trust that Current Oncology will become an invaluable resource for the Canadian oncology community. The gene for human epidermal growth factor 2 is amplified in approximately 20% of breast cancers, and the amplification is the primary mechanism for her2 protein overexpression. Overexpression of her2 is predictive of response to particular therapies, including trastuzumab (Herceptin: Genentech, San Francisco, California, U.S.A.) treatment in the meta-static and adjuvant settings, and updated Canadian guidelines for her2 testing are published in this issue of the journal. Two additional clinical practice guidelines are also included: one on the management of solitary brain metastasis, and another on the value of ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma. Stephen Sagar, in his role of section editor of Integrative Therapies, introduces a manuscript from Edzard Ernst titled “Homeopathy for cancer?” describing the evolution of the art of homeopathy over the last 200 years or so. And the National Cancer Institute of Canada (ncic) Clinical Trials Group’s article “Phase ii testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185” leads off a new section of selected Canadian Centre Activities.
Highlights
This second issue of 2007 sees the publication of the first in a series of manuscripts dedicated to the History of Oncology, with a special emphasis, initially at least, on radio-therapeutics
When Dr Laurie Elit and colleagues compared treatment and survival in ovarian cancer over two time periods in Ontario, they discovered that, age-standardized incidence and mortality rates for this disease have remained stable, advances in management have, it seems, led to a demonstrable improvement in survival for those initially treated with surgery
After nearly 40 years, new drug combinations are being explored, and the goals of the MY.11 trial from the National Cancer Institute of Canada Clinical Trials Group are discussed in this issue
Summary
When Dr Laurie Elit and colleagues compared treatment and survival in ovarian cancer over two time periods in Ontario, they discovered that, age-standardized incidence and mortality rates for this disease have remained stable, advances in management have, it seems, led to a demonstrable improvement in survival for those initially treated with surgery. This second issue of 2007 sees the publication of the first in a series of manuscripts dedicated to the History of Oncology, with a special emphasis, initially at least, on radio-therapeutics. Our European editor, Dr Richard Mould, writes the second-ever biography of the pioneering work of Pierre Curie (overshadowed to this day by the accomplishments of Marie).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
